Ultragenyx Pharmaceutical Inc
RARE31.035USD
-10.405-25.11%
Cierre 07/10, 16:00（ET）Cotizaciones retrasadas 15 min
2.91BCap. mercado
PérdidaP/E TTM
Más Datos de Ultragenyx Pharmaceutical Inc Compañía
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Información de la empresa
Símbolo de cotizaciónRARE
Nombre de la empresaUltragenyx Pharmaceutical Inc
Fecha de salida a bolsaJan 31, 2014
Fundada en2011
Director ejecutivoDr. Emil D. Kakkis, M.D., Ph.D.
Número de empleados1294
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección60 Leveroni Ct
CiudadNOVATO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94949
Teléfono14154838800
Sitio Webhttps://www.ultragenyx.com/
Símbolo de cotizaciónRARE
Fecha de salida a bolsaJan 31, 2014
Fundada en2011
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
15.69K
-83.00%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Dr. Deborah L. Dunsire, M.D.
Dr. Deborah L. Dunsire, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
Por regiónUSD
Nombre
Ganancia
Proporción
North America
57.79M
41.49%
Latin America
54.89M
39.40%
Europe
23.33M
16.75%
Japan
3.29M
2.36%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
44.96%
Investment Advisor
27.79%
Hedge Fund
21.16%
Individual Investor
3.56%
Research Firm
1.72%
Sovereign Wealth Fund
1.02%
Private Equity
0.70%
Pension Fund
0.65%
Bank and Trust
0.28%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
627
96.81M
102.40%
-2.03M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
2023Q1
609
74.12M
105.56%
-2.85M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
9.98M
10.55%
-38.64K
-0.39%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.91M
5.2%
-49.62K
-1.00%
Mar 31, 2025
Sands Capital Management, LLC
4.16M
4.4%
-134.44K
-3.13%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.14M
3.32%
+698.80K
+28.65%
Mar 31, 2025
Kakkis (Emil D)
2.69M
2.85%
-31.78K
-1.17%
Mar 07, 2025
State Street Global Advisors (US)
2.62M
2.77%
-104.13K
-3.82%
Mar 31, 2025
Wellington Management Company, LLP
2.45M
2.59%
-8.04K
-0.33%
Mar 31, 2025
ClearBridge Investments, LLC
2.26M
2.39%
-62.50K
-2.69%
Mar 31, 2025
Adage Capital Management, L.P.
2.15M
2.27%
+965.92K
+81.64%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
2.05M
2.17%
+3.00K
+0.15%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Global X Genomics & Biotechnology ETF
3.89%
Motley Fool Small-Cap Growth ETF
3%
Motley Fool Mid-Cap Growth ETF
2.01%
Franklin Genomic Advancements ETF
2%
Virtus LifeSci Biotech Products ETF
1.84%
Touchstone Sands Capital US Select Growth ETF
1.26%
WisdomTree BioRevolution Fund
1.12%
SPDR S&P Biotech ETF
0.77%
Putnam Sustainable Future ETF
0.63%
Goldman Sachs Future Health Care Equity ETF
0.6%
Ver más
Global X Genomics & Biotechnology ETF
Proporción3.89%
Motley Fool Small-Cap Growth ETF
Proporción3%
Motley Fool Mid-Cap Growth ETF
Proporción2.01%
Franklin Genomic Advancements ETF
Proporción2%
Virtus LifeSci Biotech Products ETF
Proporción1.84%
Touchstone Sands Capital US Select Growth ETF
Proporción1.26%
WisdomTree BioRevolution Fund
Proporción1.12%
SPDR S&P Biotech ETF
Proporción0.77%
Putnam Sustainable Future ETF
Proporción0.63%
Goldman Sachs Future Health Care Equity ETF
Proporción0.6%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
